Back

Daewoong presents 104-patient Bersiporocin analysis at ERS 2026

Verifying
  • Daewoong Pharmaceutical presented Bersiporocin Phase 2 patient analysis at ERS 2026.
  • 104 patients participated, including 55 South Koreans and 49 Americans.
  • Daewoong plans to announce Phase 2 top-line results in the first half of 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Daewoong presents 104-patient Bersiporocin analysis at ERS 2026 - CoinPost Terminal